StAR subfamily: StAR and MLN64
StAR -The rate-limiting step in steroidogenesis is StAR-mediated delivery of cholesterol to the P450 side chain cleavage enzyme (P450scc/Cyp11A1), which resides on the matrix side of the inner mitochondrial membrane (IMM) and converts cholesterol to pregnenolone (Fig. 3, pathway 2) (1, 15) . After stimulation by pituitary trophic hormones, acute steroidogenesis results from phosphorylation of pre-existing StAR and rapid synthesis of new StAR (15) . When StAR is mutated in humans with congenital lipoid adrenal hyperplasia (16) or knockout mice (17) , there are marked defects in steroidogenesis by adrenal cortex and gonads. Early studies did not detect StAR mRNA in other steroidogenic organs, placenta and brain (18) , but StAR expression was recently shown in both tissues (19, 20) . However, StAR null fetuses produce normal levels of placental progesterone (16) , suggesting alternate steroidogenic mechanisms.
In order for P450scc to act, cholesterol must get to the outer mitochondrial membrane (OMM), across the intermembranous space, and to the IMM. StAR is synthesized as a 37kD
protein, but the N-terminal presequence directs mitochondrial import before being cleaved in the matrix, leaving a 30kD protein. Despite its final matrix localization, StAR most likely acts at the OMM (21) . In transfection assays and studies with isolated mitochondria, StAR lacking the presequence (N-62 StAR) has equivalent activity to full-length StAR (22, 23) . In studies using StAR fusions to mitochondrial proteins, StAR at the OMM facing the cytosol is fully active, while StAR in the intermembranous space or matrix is inactive (21) . StAR could simply dropoff cholesterol, or alter the OMM to facilitate cholesterol desorption to the IMM (15) . An alternate view is that StAR must be imported to act, since data supporting an OMM site of action rely on non-physiological isolated mitochondria or transfection of non-steriodogenic cells (24 (25) . However, N-62 StAR lacks target specificity, as other acceptors include trypsin-treated mitochondria, endoplasmic reticulum (ER), and phosholipid vesicles (25, 26) . Therefore, the presequence may direct cholesterol transfer to mitochondria in preference to other organelles (15) . In addition, import may rapidly inactivate StAR (21), as StAR undergoes proteolytic degradation in mitochondria (27).
MLN64 -MLN64 was cloned as a gene amplified in breast, gastric and esophageal cancers (28, 29) . While MLN64 could play a causative role in tumorigenesis (30, 31) , amplification likely reflects close genomic proximity (within 36kB) to the oncogene c-Erb-b2 (Her-2/neu) (28) , which is invariantly co-amplified (31) . The N-terminus of MLN64 includes four transmembrane helices, while the C-terminal START domain is 37% identical to StAR (30) .
Like StAR, the isolated MLN64 START domain binds (4) and transfers (32) 
cholesterol in vitro,
and stimulates steroidogenesis when co-transfected with P450scc (31,33).
MLN64 expression is detected in all tissues (31) , and it is a candidate for StARindependent steroidogenesis in placenta. However, the transmembrane domain of MLN64 localizes it to late endosomes with the START domain facing the cytosol (32, 34) . Given this localization, full-length MLN64 is relatively inactive in steroidogenesis assays, but proteolysis could release the START domain allowing delivery of cholesterol to mitochondria (31) .
Supporting this notion, antibodies against the MLN64 START domain detect full-length protein and prominent smaller bands in placenta and transfected cells (31) .
MLN64 also functions in cholesterol mobilization from endosomes via the NiemannPick C (NPC) pathway. In NPC disease LDL-derived cholesterol accumulates in the late endosome/lysosome compartment, and two causative genes have been identified (35) . NPC2 is a soluble endosomal cholesterol-binding protein, while NPC1 is an endosomal transmembrane efflux pump that co-localizes with MLN64 (32, 34) . Endosomal cholesterol could thus move sequentially from luminal NPC2 through NPC1 to MLN64 and finally to a cytosolic acceptor (Fig. 3, pathway 1 StarD4 and StarD5 share 30% amino acid identity and are expressed in most tissues with highest levels in liver and kidney (3). In the co-transfection assay for StAR-like activity, both StarD4 and StarD5 can stimulate steroidogenesis by mitochondrial P450scc. 2 Since they are widely expressed, other roles in non-vesicular intracellular cholesterol transport have been proposed (3, 37) . Like StAR (38, 39) , StarD4 and StarD5 may also deliver cholesterol to mitochondrial Cyp27, which generates 27-hydroxycholesterol (Fig. 3, pathway 3 ). In liver, this is the initial step in alternative bile acid synthesis, a process that may be rate-limited by cholesterol delivery to mitochondria (39) . In peripheral cells, 27-hydroxycholesterol may function as an agonist for the LXR nuclear receptors (40) , which activate reverse cholesterol transport (41) , and as a more soluble oxysterol that can leave cells directly.
StarD4 -StarD4 was identified using microarrays, as hepatic StarD4 mRNA is decreased 2-3 fold on a high cholesterol diet (3). StarD4 mRNA levels are also sterol-regulated in cultured cells (3), consistent with transcriptional regulation by sterol regulatory element (SRE) binding proteins (SREBPs) (42) . Reporter transfection assays have identified a functional SRE in the StarD4 promoter. 2 Since StarD4 is coordinately regulated with SREBP2 target genes involved in cholesterol synthesis 2 , it may transport a cholesterol precursor sterol to facilitate this process (3).
StarD5 -StarD5 is not regulated by sterols, but ER stress by various agents activates
StarD5 expression 2-4 fold in cultured cells. 2 Cells respond to perturbations in ER function by the unfolded protein response (UPR), which activates transcription of ER stress response genes (43) . The ER is a sterol-poor membrane despite being the site of cholesterol synthesis (37), so sterol transport by StarD5 may help reduce ER stress.
StarD6 -StarD6 expression is limited to the testis (3), in germ cells at all developmental
stages, but not in somatic Leydig and Sertoli cells. domain. In the PCTP structure, 28 residues in the hydrophobic cavity contact PC (6) , and 20 of these are identical or similar in StarD7, including 9 of the 11 aromatics. This suggests that StarD7 may also bind PC, while StarD10 and GPBP exhibit much less similarly at these key residues (only 1 and 3 of the 11 aromatics conserved, respectively), suggesting different ligands.
PCTP -PCTP is an extremely specific lipid binding protein, as it promotes intermembrane transfer of PC but not other phospholipids or sterols (47) . PCTP is a cytosolic protein, but it relocates to mitochondria upon clofibrate treatment in some cell types, and this movement requires a putative phosphorylation site at serine 110 (48) . PCTP is widely expressed with highest levels in liver (49) , and a function has been proposed in the selective secretion of PC into bile (Fig. 3, pathway 5 ). However, PCTP knockout mice were reported with normal biliary PC levels, but even wild-type adults in this study had very low liver PCTP protein levels compared to newborn pups (50) . PCTP may also play a role in cellular lipid efflux via ATP binding cassette A1 (ABCA1), which forms plasma high density lipoproteins (HDL) by efflux of phospholipids and cholesterol to apolipoprotein AI (41) . Overexpression of PCTP results in a dose dependent acceleration of this efflux, suggesting that PCTP replenishes the plasma membrane with PCs that have been removed by ABCA1 (Fig. 3, pathway 4 ) (51).
StarD7 -There are no publications on StarD7, but over 700 expressed sequence tag cDNA clones (ESTs) from many tissues indicate abundant and widespread expression.
StarD10 -StarD10 mRNA is detectable by Northern Blot in testis, liver, kidney, and intestine (52), and there are ~700 ESTs from many tissues. In testis StarD10 is expressed in germ but not somatic cells (52) , similar to StarD6.
GPBP -The widely expressed GPBP has an N-terminal Pleckstrin homology (PH)
domain, two serine-rich domains, and a C-terminal START domain (53) . GPBP binds and phosphorylates Goodpasture (GP) antigen, the C-terminus of human collagen IV α3 which is the target of autoantibodies in GP syndrome (53) . PH domains mediate protein:protein or protein:membrane interactions, and the GPBP PH and first serine-rich domains are sufficient for binding GP antigen (53) . GPBP lacks a conventional serine/threonine kinase domain, but activity is absent in a truncated protein missing the C-terminus (53) . The location of the kinase active site is not known, but the START domain is more likely regulatory than catalytic. GPBP mRNA is alternatively spliced and the most abundant form (GPBP∆26) lacks the second serine rich domain (54) . Antibodies that recognize the rarer full length protein but not GPBP∆26 stain endothelial basement membranes -particularly in renal glomeruli and lung alveoli, which are affected in GP syndrome -and show markedly increased staining in skin biopsies from patients CACH -CACH has high hydrolase activity for acetyl-CoA (C 2 ), low activity for short chain acyl-CoAs (C 4 -C 6 ), but no activity for medium (C 12 ) and long (C 16 ) chain acyl-CoAs (56).
Rat CACH activity is detected only in liver and kidney cytosol (57) , and hepatic activity is regulated in several metabolic states. First, both starvation and a fat-free diet increase activity, suggesting that CACH regulates acetyl CoA levels for fatty acid oxidation and synthesis (57) .
Second, activity is increased by cholesterol feeding or by cholesterol synthesis inhibitors, both of which decrease cholesterol synthesis and may increase levels of the precursor acetyl CoA (58).
Third, activity is elevated in acute streptozotocin-induced diabetes, but insulin injection prevents this elevation (58) . Finally, the PPARα agonist clofibrate elevates CACH activity 3-fold (59).
The recent cloning of CACH will allow more detailed molecular and functional studies (56) .
THEA -Though the thioesterase domains of THEA and CACH are ~60% identical, no acetyl-CoA hydrolase activity was found for recombinant THEA (56), which instead hydrolyzed medium and long chain acyl-CoAs in preliminary studies (60) . Humans produce two THEA splice variants, which vary in relative abundance among tissues and encode different C-termini 
Evolutionary Perspective
The distribution of START proteins in completely sequenced genomes shows the evolutionary history of this domain (7) . The pathogenic bacterium Pseudomonas aeruginosa PA1579 gene is similar to mammalian PCTP, suggesting horizontal acquisition from hosts since there are no START genes in other prokaryotes (5) . START domains are also absent in the yeast Saccharomyces cerevisiae, but the slime mold Dictyostelium discoideum has the CheaterA START protein, indicating the domain was present in the common ancestor to multicellular eukaryotes (7). CheaterA also includes WD40 and F-box domains, suggesting a role in protein ubiquitination, and CheaterA mutants preferentially form spores rather than stalks (67) . The plant Arabidopsis thaliana has 20 START genes, 16 of which are fused to homeodomains, suggesting that ligand binding to these transcription factors may regulate plant development (2).
In animals, mammals have 15 START genes, while the fruit fly Drosophila melanogaster has only four, which most closely resemble mammalian MLN64, GPBP, PCTP/StarD7, and a RhoGAP (Fig. 1C) . The nematode C. elegans has three additional START genes -most similar to StAR, StarD10, and StarD5 -for a total of seven (Fig. 1C) . C. elegans K02D3.2 (a protein 23% identical to StarD5, but only ~17% to StarD4 or StarD6) was recently identified as a gene affecting fat storage in a genome-wide RNAi screen (68) . START genes have also been described in animals without completely sequenced genomes, including a START protein in the silkworm Bombyx mori that binds carotenoids (69) . 
Conclusion

